An announcement from ImmunityBio ( (IBRX) ) is now available.
On April 7, 2025, ImmunityBio, Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering, involving the sale of 29,024,768 shares of common stock and warrants for additional shares. This transaction is expected to generate approximately $75 million in gross proceeds, supporting the company’s ongoing business operations. The offering is anticipated to close around April 9, 2025, subject to customary conditions, and could potentially yield an additional $90 million if the warrants are fully exercised. This financing move is part of ImmunityBio’s strategy to bolster its working capital and further its development of cancer vaccines and immunotherapies.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
ImmunityBio’s financial performance indicates significant challenges, with persistent losses and high leverage posing risks to financial stability. Technical analysis shows mixed signals, with some upward momentum but overall bearish indicators. Valuation metrics are unattractive due to negative earnings. The absence of a dividend yield further diminishes its appeal.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company focused on developing next-generation therapies and vaccines that enhance the natural immune system to combat cancers and infectious diseases. The company offers a range of immunotherapy and cell therapy platforms designed to drive and sustain an immune response, aiming for durable and safe protection against diseases. Notably, ImmunityBio’s ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS.
YTD Price Performance: 5.84%
Average Trading Volume: 6,430,752
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.42B
Find detailed analytics on IBRX stock on TipRanks’ Stock Analysis page.